Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    Article  CAS  Google Scholar 

  2. Liu DH, Zhao ZR, Lin YB, et al. Prognostic Effect of TP53 and PKD Co-mutations in patients with resected epidermal growth factor receptor-mutated lung adenocarcinoma. Ann Surg Oncol. 2019;26:1934–41.

    Article  Google Scholar 

  3. Halvorsen A, Silwal-Pandit L, Meza-Zepeda L, et al. TP53 Mutation spectrum in smokers and never smoking lung cancer patients. Front Genet. 2016;7:85.

    Article  Google Scholar 

  4. Shepherd F, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2017;35(18):2018–27.

    Article  CAS  Google Scholar 

  5. Azoitei N, Cobbaut M, Becher A, et al. Protein kinase D2: a versatile player in cancer biology. Oncogene. 2018;37(10):1263–78.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Hao Long MD, PhD & Di-Han Liu MD

  2. Lung Cancer Research Center, Sun Yat-Sen University, Guangzhou, China

    Hao Long MD, PhD & Di-Han Liu MD

Authors
  1. Hao Long MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Di-Han Liu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hao Long MD, PhD.

Ethics declarations

Disclosures

Hao Long and Di-Han Liu have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ASO Author Reflections is a brief invited commentary on the article “Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma”, Ann Surg Oncol. 2019;26:1934–1941.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Long, H., Liu, DH. ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma. Ann Surg Oncol 26 (Suppl 3), 853–854 (2019). https://doi.org/10.1245/s10434-019-08079-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-08079-z

Search

Navigation